To qualify for semaglutide for weight loss, you generally need a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition. But there’s an important distinction most people miss: Ozempic itself is only FDA-approved for type 2 diabetes, not weight loss. The weight loss version of the same drug is called Wegovy, approved at a higher dose specifically for weight management. Many doctors do prescribe Ozempic off-label for weight loss, which is why the lines get blurred.
The BMI Thresholds You Need to Meet
The FDA set two paths to qualify for semaglutide for chronic weight management. The first is straightforward: a BMI of 30 or above, which is the clinical definition of obesity. At that threshold, no additional health conditions are required.
The second path applies if your BMI falls between 27 and 29.9, which is classified as overweight. In that range, you qualify if you also have at least one weight-related medical condition. The qualifying conditions include:
- Type 2 diabetes
- High blood pressure
- High cholesterol
- Obstructive sleep apnea
- Cardiovascular disease that increases your risk of heart attack or stroke
- MASH (metabolic dysfunction-associated steatohepatitis), a form of liver inflammation linked to excess fat
For reference, a BMI of 30 corresponds to roughly 186 pounds at 5’6″ or 209 pounds at 5’10”. A BMI of 27 is about 167 pounds at 5’6″ or 188 pounds at 5’10”. You can calculate yours by dividing your weight in pounds by your height in inches squared, then multiplying by 703.
Ozempic vs. Wegovy: Why the Name Matters
Ozempic and Wegovy contain the exact same active ingredient, semaglutide, but they’re approved for different purposes and at different doses. Ozempic is approved for type 2 diabetes at doses up to 1 mg per week. Wegovy is approved for weight management at 2.4 mg per week, more than double the maximum Ozempic dose.
When doctors prescribe Ozempic specifically for weight loss in someone without diabetes, that’s considered off-label use. Off-label prescribing is legal and common in medicine, but it changes a few things practically. Your insurance is less likely to cover Ozempic for weight loss since it’s not the drug’s approved indication. Some insurers cover Wegovy for weight management but not Ozempic used for the same purpose, and many don’t cover either.
The surge in off-label Ozempic prescriptions for weight loss has been driven partly by Wegovy supply shortages and partly by cost. In real-world data, about 69% of people using Ozempic off-label for weight loss did so with a doctor’s prescription, while roughly 31% self-initiated use without direct physician guidance.
Who Can’t Take It
Certain medical histories disqualify you from using semaglutide regardless of your BMI. You should not use it if you or anyone in your family has ever had medullary thyroid carcinoma (MTC), a specific type of thyroid cancer. You’re also disqualified if you have a condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), a rare genetic disorder that causes tumors in multiple glands.
A personal or family history of pancreatitis is another red flag that providers evaluate carefully before prescribing. Pregnant women should not use semaglutide, a point reinforced by the World Health Organization’s 2025 global guidelines on GLP-1 medications for obesity.
Eligibility for Teens
Wegovy is FDA-approved for adolescents aged 12 and older, but the criteria differ from adults. Instead of a fixed BMI number, teens qualify based on BMI percentile for their age and sex. The threshold is a BMI at or above the 95th percentile, which is the clinical definition of obesity in children and adolescents. Ozempic does not have a pediatric approval for weight management.
What Else Your Doctor Evaluates
Meeting the BMI threshold is necessary but not always sufficient. Semaglutide is approved as an add-on to a reduced-calorie diet and increased physical activity, not as a standalone treatment. Most prescribers will want to discuss your eating habits, exercise patterns, and previous weight loss attempts before writing a prescription. The WHO’s 2025 guidelines specifically recommend that structured behavioral interventions involving diet and physical activity be offered alongside GLP-1 medications.
Your provider will also review your full medication list for interactions and check for contraindications like the thyroid and pancreatic concerns mentioned above. If you have type 2 diabetes and already take insulin or other blood sugar-lowering medications, doses may need adjusting to avoid dangerously low blood sugar.
Some providers and insurance plans require documented evidence that you’ve tried lifestyle changes or other weight management approaches before approving semaglutide. This “step therapy” requirement varies widely between insurers. If your first request is denied, your doctor can often submit a prior authorization explaining why the medication is medically necessary for your situation.
How Prescriptions Typically Work
Semaglutide is a once-weekly injection you give yourself, usually in the stomach, thigh, or upper arm. You don’t start at the full dose. The standard approach involves a gradual dose escalation over several months, starting low to let your body adjust and minimize side effects like nausea, which is the most common complaint during the early weeks.
For Wegovy, the escalation period takes about 16 to 20 weeks before reaching the maintenance dose of 2.4 mg. For off-label Ozempic use, the maximum dose is lower at 1 mg, and the ramp-up period is shorter. Your provider determines which version and dose makes sense based on your health profile, insurance coverage, and treatment goals.